Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06227585 · ClinicalTrials.gov registry record · Phase 2
Feasibility and Efficacy Study for Bevonescein-Assisted Nerve Visualization in Head & Neck Surgery
A Phase 2 study, sponsored by Alume Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT06227585: Completed Phase 2 study, sponsored by Alume Biosciences.
NCT06227585 is a Phase 2 study that has completed, run by Alume Biosciences. The registered enrollment target is 155 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06227585, a Phase 2 study, has completed, sponsored by Alume Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
A Part 1 Phase 2 feasibility study to characterize the feasibility of using the REVEAL 475 system by obtaining surgeon perspective on illumination and ease of use. A Part 2 Phase 3 safety and efficacy study to evaluate conspicuity of the identified nerve due to bevonescein through the use of the Visualization Scoring System (VSS).
Primary Outcome
Surgeon assessment to questions
Interventions
- DRUG Bevonescein
- DEVICE REVEAL 475 System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2023-11-29 |
| Est. Completion | 2025-11-24 |
| Phase | Phase 2 |
What the finished NCT06227585 record still lists
NCT06227585 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher).
The record links to 0 conditions, and to 2 interventions - of which Bevonescein is the first listed.
NCT06227585 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06227585 about?
NCT06227585 is a clinical study titled "Feasibility and Efficacy Study for Bevonescein-Assisted Nerve Visualization in Head & Neck Surgery". A Part 1 Phase 2 feasibility study to characterize the feasibility of using the REVEAL 475 system by obtaining surgeon perspective on illumination and ease of use. A Part 2 Phase 3 safety and efficacy study to evaluate conspicuity of the identified nerve due to bevonescein through the use of the Vi...
What is the current status of trial NCT06227585?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2023-11-29. Estimated completion is 2025-11-24.
What interventions are being tested in trial NCT06227585?
The interventions under investigation include: Bevonescein (DRUG), REVEAL 475 System (DEVICE).
Who is sponsoring clinical trial NCT06227585?
This trial is sponsored by Alume Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06227585's enrollment target sits among peer trials
155 448th of 2000 higher than 1,553 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI